JP2015509973A - 結晶性ｐｉ３キナーゼ阻害剤 - Google Patents

結晶性ｐｉ３キナーゼ阻害剤 Download PDF

Info

Publication number
JP2015509973A
JP2015509973A JP2014561515A JP2014561515A JP2015509973A JP 2015509973 A JP2015509973 A JP 2015509973A JP 2014561515 A JP2014561515 A JP 2014561515A JP 2014561515 A JP2014561515 A JP 2014561515A JP 2015509973 A JP2015509973 A JP 2015509973A
Authority
JP
Japan
Prior art keywords
compound
formula
lactose
solid crystalline
anhydrous form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014561515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509973A5 (cg-RX-API-DMAC7.html
Inventor
ブロークス，ルデイ・ローラン・マリア
フイリエール，ワルター・フエルデイナンド・マリア
ニーステ，パトリク・ユベール・ジエイ
コプマン，アレツクス・ヘルマン
バンウツト，フイリツプ・マルセル・シー
レイズ，カリナ
Original Assignee
レスピバート・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015509973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by レスピバート・リミテツド filed Critical レスピバート・リミテツド
Publication of JP2015509973A publication Critical patent/JP2015509973A/ja
Publication of JP2015509973A5 publication Critical patent/JP2015509973A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014561515A 2012-03-13 2013-03-13 結晶性ｐｉ３キナーゼ阻害剤 Pending JP2015509973A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13
US61/610,023 2012-03-13
US61/610,012 2012-03-13
PCT/GB2013/050624 WO2013136076A1 (en) 2012-03-13 2013-03-13 Crystalline pi3 kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017151378A Division JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性ｐｉ３キナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2015509973A true JP2015509973A (ja) 2015-04-02
JP2015509973A5 JP2015509973A5 (cg-RX-API-DMAC7.html) 2016-04-14

Family

ID=49160309

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014561515A Pending JP2015509973A (ja) 2012-03-13 2013-03-13 結晶性ｐｉ３キナーゼ阻害剤
JP2014561514A Expired - Fee Related JP6189874B2 (ja) 2012-03-13 2013-03-13 新規製薬学的製剤
JP2017151378A Withdrawn JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性ｐｉ３キナーゼ阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014561514A Expired - Fee Related JP6189874B2 (ja) 2012-03-13 2013-03-13 新規製薬学的製剤
JP2017151378A Withdrawn JP2018008992A (ja) 2012-03-13 2017-08-04 結晶性ｐｉ３キナーゼ阻害剤

Country Status (35)

Country Link
US (3) US20150099768A1 (cg-RX-API-DMAC7.html)
EP (2) EP2834244B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015509973A (cg-RX-API-DMAC7.html)
KR (2) KR20140131971A (cg-RX-API-DMAC7.html)
CN (2) CN104284679B (cg-RX-API-DMAC7.html)
AU (2) AU2013234080B2 (cg-RX-API-DMAC7.html)
CA (2) CA2864652A1 (cg-RX-API-DMAC7.html)
CL (2) CL2014002386A1 (cg-RX-API-DMAC7.html)
CO (2) CO7051030A2 (cg-RX-API-DMAC7.html)
CR (2) CR20140416A (cg-RX-API-DMAC7.html)
CY (1) CY1118565T1 (cg-RX-API-DMAC7.html)
DK (1) DK2834244T3 (cg-RX-API-DMAC7.html)
EA (2) EA023715B1 (cg-RX-API-DMAC7.html)
EC (2) ECSP14018142A (cg-RX-API-DMAC7.html)
ES (2) ES2650791T3 (cg-RX-API-DMAC7.html)
GT (2) GT201400182A (cg-RX-API-DMAC7.html)
HR (1) HRP20161383T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029420T2 (cg-RX-API-DMAC7.html)
IL (2) IL233886A (cg-RX-API-DMAC7.html)
IN (2) IN2014MN02000A (cg-RX-API-DMAC7.html)
LT (1) LT2834244T (cg-RX-API-DMAC7.html)
MX (2) MX355299B (cg-RX-API-DMAC7.html)
MY (1) MY171125A (cg-RX-API-DMAC7.html)
NI (2) NI201400100A (cg-RX-API-DMAC7.html)
NZ (2) NZ628072A (cg-RX-API-DMAC7.html)
PE (2) PE20142342A1 (cg-RX-API-DMAC7.html)
PH (2) PH12014501713A1 (cg-RX-API-DMAC7.html)
PL (1) PL2834244T3 (cg-RX-API-DMAC7.html)
PT (1) PT2834244T (cg-RX-API-DMAC7.html)
SG (2) SG11201404522VA (cg-RX-API-DMAC7.html)
SI (1) SI2834244T1 (cg-RX-API-DMAC7.html)
TW (2) TWI617561B (cg-RX-API-DMAC7.html)
UA (1) UA115544C2 (cg-RX-API-DMAC7.html)
WO (2) WO2013136076A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201407373B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2916868B1 (en) 2012-11-08 2022-05-11 Rhizen Pharmaceuticals S.A. Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
EP3164400A1 (en) 2014-07-04 2017-05-10 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
ES2701525T3 (es) * 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
JP7166929B2 (ja) * 2016-04-15 2022-11-08 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
WO2011048111A1 (en) * 2009-10-19 2011-04-28 Respivert Limited Compounds
JP2011153136A (ja) * 2010-01-07 2011-08-11 Pfizer Ltd ビフェニル−２−イル−カルバミン酸１−｛９−［（３−フルオロ−４−ヒドロキシ−ベンゾイル）−メチル−アミノ］−ノニル｝−ピペリジン−４−イルエステル塩酸塩
WO2012028663A1 (en) * 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
ATE382386T1 (de) 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Ｎａｄシンテターゼ阻害剤およびその使用
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
CA2520121A1 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
CN102229609A (zh) * 2004-05-13 2011-11-02 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
US20080032960A1 (en) 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
CN101448505A (zh) * 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
WO2007134876A2 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
CN101506198A (zh) 2006-06-29 2009-08-12 先灵公司 取代的双环和三环凝血酶受体拮抗剂
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
JP2010510177A (ja) 2006-11-17 2010-04-02 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害を治療するための化合物および方法
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
AR066477A1 (es) 2007-05-09 2009-08-19 Novartis Ag Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US20110294803A1 (en) 2008-12-04 2011-12-01 Law Amanda J Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
JP2013501008A (ja) 2009-08-05 2013-01-10 バーシテック リミテッド 抗ウイルス性化合物ならびにそれを含む医薬組成物
CN201676365U (zh) * 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) * 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
KR101886987B1 (ko) 2010-09-30 2018-08-08 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제 내 마그네슘 스테아레이트의 용도
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) * 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
SG11201404522VA (en) 2012-03-13 2014-10-30 Respivert Ltd Crystalline pi3 kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
WO2011048111A1 (en) * 2009-10-19 2011-04-28 Respivert Limited Compounds
JP2011153136A (ja) * 2010-01-07 2011-08-11 Pfizer Ltd ビフェニル−２−イル−カルバミン酸１−｛９−［（３−フルオロ−４−ヒドロキシ−ベンゾイル）−メチル−アミノ］−ノニル｝−ピペリジン−４−イルエステル塩酸塩
WO2012028663A1 (en) * 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
平山令明, 有機化合物結晶作製ハンドブック, JPN6014022315, 2008, pages 10 - 11, ISSN: 0003394635 *

Also Published As

Publication number Publication date
US20150105408A1 (en) 2015-04-16
MX357170B (es) 2018-06-27
KR20140141596A (ko) 2014-12-10
MX2014010990A (es) 2014-10-13
MX2014010991A (es) 2014-10-13
ES2600705T3 (es) 2017-02-10
TW201350139A (zh) 2013-12-16
HUE029420T2 (en) 2017-02-28
AU2013234080A1 (en) 2014-08-21
CA2864652A1 (en) 2013-09-19
PE20142342A1 (es) 2015-01-16
CN104284679A (zh) 2015-01-14
AU2013234081B2 (en) 2017-02-02
JP2018008992A (ja) 2018-01-18
WO2013136075A1 (en) 2013-09-19
US20170239256A1 (en) 2017-08-24
EA201491674A1 (ru) 2014-12-30
GT201400183A (es) 2015-07-08
EP2825202B1 (en) 2017-09-06
CA2864643A1 (en) 2013-09-19
CN104302650A (zh) 2015-01-21
TW201400484A (zh) 2014-01-01
CN104284679B (zh) 2017-08-04
PT2834244T (pt) 2016-11-03
GT201400182A (es) 2015-09-17
CY1118565T1 (el) 2017-07-12
CO7061079A2 (es) 2014-09-19
HRP20161383T1 (hr) 2016-12-02
TWI617561B (zh) 2018-03-11
UA115544C2 (uk) 2017-11-27
EA201491675A1 (ru) 2014-12-30
EA025465B1 (ru) 2016-12-30
JP2015509972A (ja) 2015-04-02
TWI586378B (zh) 2017-06-11
US9642799B2 (en) 2017-05-09
SI2834244T1 (sl) 2016-12-30
CO7051030A2 (es) 2014-09-10
PH12014501922A1 (en) 2014-11-24
US20150099768A1 (en) 2015-04-09
EP2834244A1 (en) 2015-02-11
AU2013234081A1 (en) 2014-08-21
ECSP14018630A (es) 2015-09-30
NI201400101A (es) 2016-11-30
EP2834244B1 (en) 2016-08-10
IN2014MN01998A (cg-RX-API-DMAC7.html) 2015-08-14
MY171125A (en) 2019-09-26
CN104302650B (zh) 2017-07-18
WO2013136076A1 (en) 2013-09-19
HK1203812A1 (en) 2015-11-06
CL2014002385A1 (es) 2015-01-09
AU2013234080B2 (en) 2016-12-22
PE20141964A1 (es) 2014-12-01
NZ627963A (en) 2015-08-28
ES2650791T3 (es) 2018-01-22
CR20140416A (es) 2014-10-31
ZA201407373B (en) 2016-10-26
ECSP14018142A (es) 2015-06-30
SG11201404522VA (en) 2014-10-30
NI201400100A (es) 2015-01-12
MX355299B (es) 2018-04-11
HK1203487A1 (zh) 2015-10-30
PH12014501713A1 (en) 2014-10-13
ZA201407374B (en) 2016-10-26
IL233886A (en) 2017-12-31
NZ628072A (en) 2015-08-28
IN2014MN02000A (cg-RX-API-DMAC7.html) 2015-08-14
CL2014002386A1 (es) 2015-02-27
EA023715B1 (ru) 2016-07-29
CR20140417A (es) 2014-10-31
LT2834244T (lt) 2016-11-10
DK2834244T3 (en) 2016-11-28
EP2825202A1 (en) 2015-01-21
SG11201404519UA (en) 2014-10-30
IL233883A0 (en) 2014-09-30
PL2834244T3 (pl) 2017-01-31
JP6189874B2 (ja) 2017-08-30
KR20140131971A (ko) 2014-11-14

Similar Documents

Publication Publication Date Title
JP6189874B2 (ja) 新規製薬学的製剤
JP6353856B2 (ja) ２−（（４−アミノ−３−（３−フルオロ−５−ヒドロキシフェニル）−１ｈ−ピラゾロ［３，４−ｄ］ピリミジン−１−イル）メチル）−３−（２−トリフルオロ−メチル）ベンジル）キナゾリン−４（３ｈ）−オン誘導体及びホスホイノシチド３−キナーゼ阻害剤としてのそれらの使用
HK1203487B (en) Crystalline pi3 kinase inhibitors
HK1203812B (en) Stabilization of pharmaceutical compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170915

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171004

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20171027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180710